西妥昔单抗联合雷替曲塞用于接受过西妥昔单抗联合化疗的初始RAS/BRAF野生型转移性结直肠癌患者的疗效  

Clinical efficacy of cetuximab combined with raltitrexed in patients with initial RAS/BRAF wild-type metastatic colorectal cancer received cetuximab combined chemotherapy before

作　　者：徐海源[1] 计张奕[1] 徐燕[1] 沈刚[1] XU Haiyuan;JI Zhangyi;XU Yan;SHEN Gang(Department of Medical Oncology,Affiliated Kunshan First People's Hospital,Jiangsu University,Kunshan 215300,CHINA)

机构地区：[1]江苏大学附属昆山市第一人民医院肿瘤科,江苏昆山215300

出　　处：《江苏医药》2025年第2期180-184,共5页Jiangsu Medical Journal

摘　　要：目的观察西妥昔单抗联合雷替曲塞用于接受过西妥昔单抗联合化疗的初始RAS/BRAF野生型转移性结直肠癌患者的临床疗效。方法回顾性分析23例接受过西妥昔单抗联合化疗的初始RAS/BRAF野生型转移性结直肠癌患者的临床资料。第1天给予西妥昔单抗500mg/m^(2)静脉滴注2h联合雷替曲塞2mg/m^(2)静脉滴注15min,每14天为1个治疗周期,治疗≥4个治疗周期。根据实体瘤疗效评价标准和化疗毒性分级标准评估临床疗效和安全性。结果23例患者均顺利完成≥4个治疗周期的治疗,部分缓解6例,疾病稳定10例,疾病进展PD 7例,客观缓解率26.1%,疾病控制率69.6%。中位无进展生存期4.1个月,中位总生存期16.5个月,不良反应主要为血液学毒性(白细胞减少、中性粒细胞减少及贫血)和粉刺样皮疹。结论西妥昔单抗联合雷替曲塞具有一定的临床疗效,不良反应较轻,可推荐用于接受过西妥昔单抗联合化疗的初始RAS/BRAF野生型转移性结直肠癌患者的再治疗。Objective To observe the clinical efficacy of cetuximab combined with raltitrexed in patients with initial RAS/BRAF wild-type metastatic colorectal cancer received cetuximab combined chemotherapy before.Methods The clinical data of 23 patients with intial RAS/BRAF wild-type metastatic colorectal cancer received cetuximab combined chemotherapy before were retrospectively analyzed.On the first day,cetuximab 500mg/m^(2) was given intravenously for 2 hours and rhatitrexed 2mg/m^(2) was given intravenously for 15 minutes.Every 14 days was one treatment cycle,with≥4 treatment cycles of therapy.The clinical efficacy and safety were evaluated according to response evaluation criteria in solid tumors and chemotherapy toxicity grading criteria.Results All the 23 patients successfully completed≥4 treatment cycles of therapy,with 6 cases of partial remission,10 cases of disease stability,and 7 cases of disease progression.The objective remission rate was 26.1%,and the disease control rate was 69.6%.Median progression-free survival was 4.1 months and median overall survival was 16.5 months.The main adverse events were hematologic toxicity(leukopenia,neutropenia and anemia)and comedoid rash.Conclusion Cetuximab combined with raltitrexed has certain clinical efficacy and mild adverse reactions,and can be recommended for retreatment of patients with initial RAS/BRAF wild-type metastatic colorectal cancer received cetuximab combined chemotherapy before.

关 键 词：西妥昔单抗 雷替曲塞 转移性结直肠癌 

分 类 号：R735[医药卫生—肿瘤]